Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in J Rheumatol Retrieve available abstracts of 121 articles: HTML format

Single Articles

October 2025
1. OGBONNAYA SA, Williams S, Lightbourne M, Brown RJ, et al
   Type B Insulin Resistance: A Case Report of a Rare Complication of Systemic Lupus Erythematosus.
   J Rheumatol. 2025 Oct 15:jrheum.2025-0533. doi: 10.3899/jrheum.2025-0533.
   PubMed    
   
   
   
2. SRINIVASALU H, Beukelman T, Dennos A, Chen A, et al
   Juvenile Psoriatic Arthritis Inception Cohort in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Characteristics and Early Disease Outcomes.
   J Rheumatol. 2025;52:1013-1020.
   PubMed     Abstract available
   
   
   
3. PONGTARAKULPANIT N, Bishnoi A, Chandra T, Dzanko S, et al
   Quantifying Cutaneous Dermatomyositis: A Novel 3D Image-based Approach.
   J Rheumatol. 2025 Oct 1:jrheum.2025-0537. doi: 10.3899/jrheum.2025-0537.
   PubMed     Abstract available
   
   
   
4. LOPEZ-MARTINEZ J, Esplugues Clos J, Fernandez-Valmana A, Feijoo-Masso C, et al
   Renal AA Amyloidosis Associated With Systemic Lupus Erythematosus Treated With Anakinra.
   J Rheumatol. 2025 Oct 1:jrheum.2025-0431. doi: 10.3899/jrheum.2025-0431.
   PubMed    
   
   
   
5. MAYO-JUANATEY A, Castaneda S, Calvo-Rio V, Garijo-Bufort M, et al
   Anifrolumab in Systemic Lupus Erythematosus With Severe Hematological Manifestations: A Spanish Multicenter Study.
   J Rheumatol. 2025 Oct 1:jrheum.2025-0658. doi: 10.3899/jrheum.2025-0658.
   PubMed    
   
   
   
6. RUBINSTEIN TB, Touma Z, Blanco I, Knight AM, et al
   Improving Mental Health Care for People With Systemic Lupus Erythematosus: Time to Take Action.
   J Rheumatol. 2025 Oct 1:jrheum.2025-0922. doi: 10.3899/jrheum.2025-0922.
   PubMed    
   
   
   September 2025
7. SINGH JA, Beasley M
   Patient Resilience is associated with Better Patient-Reported Physical and Mental/Emotional Quality of Life in Systemic Lupus Erythematosus.
   J Rheumatol. 2025 Sep 15:jrheum.2025-0396. doi: 10.3899/jrheum.2025-0396.
   PubMed     Abstract available
   
   
   
8. YAU E, Chim T, Lim M, Inman RD, et al
   Anti-Integrin alphavbeta6 Autoantibodies as a Biomarker for Ulcerative Colitis in Patients With Axial Spondyloarthritis.
   J Rheumatol. 2025 Sep 15:jrheum.2024-1296. doi: 10.3899/jrheum.2024-1296.
   PubMed     Abstract available
   
   
   
9. YE C, Nikolic RPA, Choi M, Fifi-Mah AV, et al
   Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisti
   J Rheumatol. 2025 Sep 15:jrheum.2025-0482. doi: 10.3899/jrheum.2025-0482.
   PubMed     Abstract available
   
   
   
10. CONSOLARO A, Ruperto N, Lovell DJ, Synoverska O, et al
    Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.
    J Rheumatol. 2025;52:919-926.
    PubMed     Abstract available
    
    
    
11. JUNEK ML, Chanchlani R, Rodriguez AR, Khalidi N, et al
    Assessment of giant cell arteritis-associated visual outcomes at a tertiary hospital in Ontario, Canada.
    J Rheumatol. 2025 Sep 1:jrheum.2025-0459. doi: 10.3899/jrheum.2025-0459.
    PubMed     Abstract available
    
    
    
12. ZAFFINO I, Boulard L, Law J, Danguecan A, et al
    Individual and Socio-ecological Resilience in Childhood-Onset Systemic Lupus Erythematosus: Associations with Patient Characteristics and Psychosocial Patient-Reported Outcomes.
    J Rheumatol. 2025 Sep 1:jrheum.2025-0375. doi: 10.3899/jrheum.2025-0375.
    PubMed     Abstract available
    
    
    
13. LIN CH, Lin YP
    Classic Magnetic Resonance Imaging Features Unmask Progressive Multifocal Leukoencephalopathy in Rituximab-Treated Neuropsychiatric Systemic Lupus Erythematosus.
    J Rheumatol. 2025 Sep 1:jrheum.2025-0410. doi: 10.3899/jrheum.2025-0410.
    PubMed    
    
    
    
14. HORN KW, Breneman A, Djavid AR, Boneparth AD, et al
    A Rare and Severe Cutaneous Presentation of Systemic Lupus Erythematosus.
    J Rheumatol. 2025 Sep 1:jrheum.2025-0367. doi: 10.3899/jrheum.2025-0367.
    PubMed    
    
    
    August 2025
15. PEDERSEN MJ, Host C, Hansen SN, Klotsche J, et al
    School Absence Among Children With Juvenile Idiopathic Arthritis: A National Matched Comparison Study.
    J Rheumatol. 2025;52:801-809.
    PubMed     Abstract available
    
    
    
16. ZIEMBA YC, Elkin EP, Kazemian E, Wilson BM, et al
    COVID-19 vaccine booster uptake and effectiveness among persons with systemic autoimmune and rheumatic diseases.
    J Rheumatol. 2025 Aug 1:jrheum.2025-0535. doi: 10.3899/jrheum.2025-0535.
    PubMed     Abstract available
    
    
    July 2025
17. EL TAL T, Steiman A, Knight A, Hiraki LT, et al
    A Pediatric-Adult Provider Dyad Care Model Improves Transition From Pediatric to Adult Healthcare For Youth with Childhood-onset Systemic Lupus Erythematosus.
    J Rheumatol. 2025 Jul 25:jrheum.2025-0046. doi: 10.3899/jrheum.2025-0046.
    PubMed     Abstract available
    
    
    
18. BRUNI C, Elhai M, Distler O
    Personalizing Management of Systemic Sclerosis-Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?
    J Rheumatol. 2025 Jul 15:jrheum.2025-0692. doi: 10.3899/jrheum.2025-0692.
    PubMed    
    
    
    
19. PATEL H, DeMasters D, Tofferi J
    Antinuclear Antibody Multiplex Utilization Across a Large Federal Hospital System: An Investigation of Ordering Practices and Rheumatologic Outcomes.
    J Rheumatol. 2025;52:721-727.
    PubMed     Abstract available
    
    
    
20. KHAROUF F, Mehta P, Alhadri A, Li Q, et al
    Comparative Analysis of Damage Accrual in Lupus Nephritis Stratified by Biological Sex.
    J Rheumatol. 2025 Jul 1:jrheum.2025-0302. doi: 10.3899/jrheum.2025-0302.
    PubMed     Abstract available
    
    
    
21. KHAROUF F, Mehta P, Li Q, Gladman DD, et al
    Comparison of Lupus Nephritis Onset Before and After Age 50: Impact on Presentation and Outcomes in an Inception Cohort.
    J Rheumatol. 2025 Jul 1:jrheum.2024-1278. doi: 10.3899/jrheum.2024-1278.
    PubMed     Abstract available
    
    
    
22. TEAW S, Shojaee A, Carnaru M, Hinchcliff M, et al
    The Risk and Time Course for Autoimmune Rheumatic Disease Development in Patients With Raynaud Phenomenon.
    J Rheumatol. 2025 Jul 1:jrheum.2024-0954. doi: 10.3899/jrheum.2024-0954.
    PubMed    
    
    
    
23. COHEN-HAGAI K, Saban M, Benchetrit S, Bar-Ziv D, et al
    Prevalence, Risk Factors, and Outcomes of Chronic Kidney Disease in Systemic Lupus Erythematosus Patients with and without Lupus Nephritis.
    J Rheumatol. 2025 Jul 1:jrheum.2024-1087. doi: 10.3899/jrheum.2024-1087.
    PubMed     Abstract available
    
    
    
24. JUNEK ML, Okaj I, Patel S, Hu A, et al
    Multivariable models to predict a diagnosis of Giant Cell Arteritis: systematic review and meta-analysis.
    J Rheumatol. 2025 Jul 1:jrheum.2022-1204. doi: 10.3899/jrheum.2022-1204.
    PubMed     Abstract available
    
    
    
25. SMITH JD, Pan B, Keeling S
    Identifying the State of Mental Health Care in Canadian Adults with Systemic Lupus Erythematosus.
    J Rheumatol. 2025 Jul 1:jrheum.2025-0089. doi: 10.3899/jrheum.2025-0089.
    PubMed     Abstract available
    
    
    May 2025
26. GUNGORER V, Celik IK, Artac H, Celikel Acar B, et al
    OTULIN-Related Autoinflammatory Syndrome With a Novel Mutation Treated With Tumor Necrosis Factor Inhibitor Therapy: A Rare Case Report.
    J Rheumatol. 2025 May 15:jrheum.2024-1141. doi: 10.3899/jrheum.2024-1141.
    PubMed    
    
    
    
27. PIRES DA ROSA G, Granja BV, Azevedo F, Magina S, et al
    Pyoderma Gangrenosum-Associated Autoinflammatory Syndrome With Skin Abscesses: Successful Treatment With Anti-Interleukin 1 Therapy.
    J Rheumatol. 2025 May 15:jrheum.2025-0036. doi: 10.3899/jrheum.2025-0036.
    PubMed    
    
    
    
28. RODRIGUEZ-REYNA TS
    The Nuances of Shared Autoimmunity and the Singularity of Mixed Connective Tissue Disease.
    J Rheumatol. 2025 May 15:jrheum.2025-0463. doi: 10.3899/jrheum.2025-0463.
    PubMed    
    
    
    
29. JIANG Z, Barra L
    Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
    J Rheumatol. 2025 May 15:jrheum.2025-0423. doi: 10.3899/jrheum.2025-0423.
    PubMed    
    
    
    
30. PLANTINGA LC, Roberts ET, Hoge C, Pearce BD, et al
    Indicators of Functional Disability by Receipt of Disability Benefits Among Individuals With Systemic Lupus Erythematosus.
    J Rheumatol. 2025;52:479-488.
    PubMed     Abstract available
    
    
    
31. PATTERSON SL, Ruvalcaba D, Issa A, Rai K, et al
    Experiences with Complementary and Integrative Health Among People with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Qualitative Study.
    J Rheumatol. 2025 May 1:jrheum.2024-1218. doi: 10.3899/jrheum.2024-1218.
    PubMed     Abstract available
    
    
    
32. KIM H
    Interferon Response Gene Score in Juvenile Dermatomyositis.
    J Rheumatol. 2025 May 1:jrheum.2025-0395. doi: 10.3899/jrheum.2025-0395.
    PubMed    
    
    
    March 2025
33. FETERMAN JIMENEZ D, Thomason JL, Liew JW, Ferguson S, et al
    Delays in Tocilizumab Therapy for Patients With Giant Cell Arteritis in the United States.
    J Rheumatol. 2025 Mar 15:jrheum.2024-0988. doi: 10.3899/jrheum.2024-0988.
    PubMed     Abstract available
    
    
    
34. ICHIKAWA T, Kishida D, Shimojima Y, Yajima N, et al
    Trust in Health Information Sources Among Patients with Systemic Lupus Erythematosus in the Social Networking Era: The TRUMP(2)-SLE Study.
    J Rheumatol. 2025 Mar 15:jrheum.2024-1088. doi: 10.3899/jrheum.2024-1088.
    PubMed     Abstract available
    
    
    
35. MACMAHON J, Massumi M, Duong TT, Garrett RH, et al
    Interferon Response Gene Score in Juvenile Dermatomyositis Correlates Strongly with Disease Activity.
    J Rheumatol. 2025 Mar 15:jrheum.2024-0806. doi: 10.3899/jrheum.2024-0806.
    PubMed     Abstract available
    
    
    
36. GENER KR, Simakova E, Handal M
    Concurrent IgG4-Related Disease and Giant Cell Arteritis: A Rare Case Study.
    J Rheumatol. 2025 Mar 1:jrheum.2024-0861. doi: 10.3899/jrheum.2024-0861.
    PubMed    
    
    
    
37. AGUILA T, Madan R, Palmer MB, Derk CT, et al
    Zebra Bodies in Kidney Biopsy: Drug-Induced Phospholipidosis in a Patient With Systemic Lupus Erythematosus.
    J Rheumatol. 2025 Mar 1:jrheum.2024-1312. doi: 10.3899/jrheum.2024-1312.
    PubMed    
    
    
    February 2025
38. HIGHLAND KB, Chakravarty R, Georgi S, Han M, et al
    Patient Perspectives and Clinical Insights Into the Diagnostic Journey From Connective Tissue Disease to Pulmonary Arterial Hypertension.
    J Rheumatol. 2025 Feb 20:jrheum.2024-0613. doi: 10.3899/jrheum.2024-0613.
    PubMed    
    
    
    
39. AFLAKI M, Bargman JM
    Urine Protein Tests in Systematic Lupus Erythematosus: What Do They Mean?
    J Rheumatol. 2025 Feb 15:jrheum.2024-0910. doi: 10.3899/jrheum.2024-0910.
    PubMed     Abstract available
    
    
    
40. STOUSTRUP P, Kellenberger CJ, Host C, Kuseler A, et al
    Effects of Biologics on Temporomandibular Joint Inflammation in Juvenile Idiopathic Arthritis.
    J Rheumatol. 2025;52:173-180.
    PubMed     Abstract available
    
    
    
41. MUMTAZ S, Koster MJ, Warrington KJ
    Novel Photon-Counting Computed Tomography for the Evaluation of Large-Vessel Giant Cell Arteritis.
    J Rheumatol. 2025 Feb 1:jrheum.2024-1156. doi: 10.3899/jrheum.2024-1156.
    PubMed    
    
    
    
42. NISHAT F, Golding M, Merrill K, Protudjer JLP, et al
    Lived Education Experience of Young Adults with Childhood- and Adult-onset Systemic Lupus Erythematosus: A Multi-Centre Canadian Qualitative Study.
    J Rheumatol. 2025 Feb 1:jrheum.2024-0695. doi: 10.3899/jrheum.2024-0695.
    PubMed     Abstract available
    
    
    
43. ABEL G, Ansari MQ, Snyder MR, Tebo AE, et al
    Historical Perspective on Antinuclear Antibody Testing.
    J Rheumatol. 2025 Feb 1:jrheum.2023-1121. doi: 10.3899/jrheum.2023-1121.
    PubMed     Abstract available
    
    
    December 2024
44. GONZALEZ-GAY MA, Castaneda S, Ferraz-Amaro I
    Managing Giant Cell Arteritis With Tocilizumab: Relapses and Adverse Events.
    J Rheumatol. 2024 Dec 15:jrheum.2024-1204. doi: 10.3899/jrheum.2024-1204.
    PubMed    
    
    
    
45. HASLAK F, Kilic H, Sahin S, Hotaman B, et al
    Children With Type I Interferonopathy: Commonalities and Diversities in a Large Patient Cohort.
    J Rheumatol. 2024;51:1208-1217.
    PubMed     Abstract available
    
    
    
46. MAILLE M, Tounkara BS, Vagner D, Bagny K, et al
    Epidemiology of isolated Cutaneous Lupus Erythematosus in the multiethnic population of Reunion Island (France): a retrospective multicentric study.
    J Rheumatol. 2024 Dec 1:jrheum.2024-0661. doi: 10.3899/jrheum.2024-0661.
    PubMed     Abstract available
    
    
    November 2024
47. NAGASE FN, Fukui S, Takizawa N, Yamaguchi T, et al
    Tocilizumab for Giant Cell Arteritis: Clinical Outcomes Following Relapses and Tocilizumab Discontinuation Due to Adverse Events.
    J Rheumatol. 2024 Nov 15:jrheum.2024-0612. doi: 10.3899/jrheum.2024-0612.
    PubMed     Abstract available
    
    
    
48. PARIMI VP, Ravindran V
    Cardiovascular Health and Adverse Pregnancy Outcomes in Autoimmune Rheumatic Diseases.
    J Rheumatol. 2024 Nov 15:jrheum.2024-0828. doi: 10.3899/jrheum.2024-0828.
    PubMed    
    
    
    
49. RANDELL RL, Reeve BB, Weitzman ER, von Scheven E, et al
    Pain Interference in Juvenile Idiopathic Arthritis.
    J Rheumatol. 2024;51:1119-1124.
    PubMed     Abstract available
    
    
    
50. IMAI Y, Ota Y, Matsumoto K, Akiyama M, et al
    Performance of the 2022 ACR/EULAR Classification Criteria in Comparison With the European Medicines Agency Algorithm in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    J Rheumatol. 2024;51:1102-1110.
    PubMed     Abstract available
    
    
    
51. BRUNNER HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, et al
    Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.
    J Rheumatol. 2024;51:1125-1134.
    PubMed     Abstract available
    
    
    
52. LIEBER SB, Young SR, Shea Y, Gottesman SP, et al
    The Lived Experiences of Older Adults with Systemic Lupus Erythematosus: Patient Perspectives.
    J Rheumatol. 2024 Nov 1:jrheum.2024-0478. doi: 10.3899/jrheum.2024-0478.
    PubMed     Abstract available
    
    
    
53. ARDALAN K, Rider LG
    Ringing in the Patient Voice: Measuring Patients' Lived Experience of Dermatomyositis Symptoms.
    J Rheumatol. 2024 Nov 1:jrheum.2024-0951. doi: 10.3899/jrheum.2024-0951.
    PubMed     Abstract available
    
    
    
54. JIANG Y, Duarte-Garcia A, Putman M, Gazeley D, et al
    Incidence of Pneumocystis jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus.
    J Rheumatol. 2024 Nov 1:jrheum.2023-1038. doi: 10.3899/jrheum.2023-1038.
    PubMed     Abstract available
    
    
    October 2024
55. LIU X, Zhang J, Xu H, Kuang W, et al
    Epidemiological characteristics of patients with juvenile dermatomyositis in China: a multicenter study.
    J Rheumatol. 2024 Oct 15:jrheum.2024-0003. doi: 10.3899/jrheum.2024-0003.
    PubMed     Abstract available
    
    
    
56. ZAREK J, Lee J, Harakati D, Spitzer K, et al
    Vitamin K Antagonists for Pregnant Women With Antiphospholipid Antibodies: A Scoping Review.
    J Rheumatol. 2024;51:964-972.
    PubMed     Abstract available
    
    
    
57. OCAMPO-TORRES MC, Hernandez-Molina G, Criales-Vera S, Sanchez-Guerrero J, et al
    Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus.
    J Rheumatol. 2024;51:991-996.
    PubMed     Abstract available
    
    
    
58. NIETO RE, Alarcon GS, Arnaud L, Pons-Estel GJ, et al
    Finding the Role of Anifrolumab in the New Paradigm of Systemic Lupus Erythematosus Treatment.
    J Rheumatol. 2024 Oct 1:jrheum.2024-0900. doi: 10.3899/jrheum.2024-0900.
    PubMed     Abstract available
    
    
    September 2024
59. VYZHGA Y, Doria AS, Feldman BM, Tse SM, et al
    Mining for Gems: Early Detection of Calcinosis in Juvenile Dermatomyositis Using Low-Dose Computed Tomography.
    J Rheumatol. 2024 Sep 15:jrheum.2024-0594. doi: 10.3899/jrheum.2024-0594.
    PubMed     Abstract available
    
    
    
60. KUWANA M, Wakasugi N, Hashida T, Uno S, et al
    Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan.
    J Rheumatol. 2024 Sep 15:jrheum.2024-0379. doi: 10.3899/jrheum.2024-0379.
    PubMed     Abstract available
    
    
    
61. AN J, Marwaha A, Laxer RM
    Autoinflammatory Diseases: A Review.
    J Rheumatol. 2024;51:848-861.
    PubMed     Abstract available
    
    
    August 2024
62. AIRES BP, Wobma H, Samad A, Chandler MT, et al
    Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease.
    J Rheumatol. 2024;51:811-817.
    PubMed     Abstract available
    
    
    
63. KARABUKAYEVA A, Hearld LR, Choi S, Singh JA, et al
    Patient Perspectives on a Decision Aid for Systemic Lupus Erythematosus: Insights and Future Considerations.
    J Rheumatol. 2024;51:798-803.
    PubMed     Abstract available
    
    
    
64. PEDERSEN MJ, Host C, Hansen SN, Klotsche J, et al
    School Well-Being and Academic Performance of Children With Juvenile Idiopathic Arthritis: A National Register-Based Study.
    J Rheumatol. 2024;51:804-810.
    PubMed     Abstract available
    
    
    
65. GOLDER V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, et al
    Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
    J Rheumatol. 2024;51:790-797.
    PubMed     Abstract available
    
    
    
66. OKITA Y, Okamoto M, Fujimoto J, Kumanogoh A, et al
    Pneumocephalus and Cerebral Abscess in Granulomatosis With Polyangiitis.
    J Rheumatol. 2024;51:832.
    PubMed    
    
    
    
67. YAMADA H, Sugiyama T, Ito Y, Toriihara A, et al
    Detection of Pancreatitis and Protein-Losing Gastroenteropathy Associated With Systemic Lupus Erythematosus by Protein Leakage Scintigraphy.
    J Rheumatol. 2024 Aug 1:jrheum.2024-0468. doi: 10.3899/jrheum.2024-0468.
    PubMed     Abstract available
    
    
    
68. CHRISTOPHER-STINE L, Ciesluk A, Chinoy H, Goyal NA, et al
    The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms.
    J Rheumatol. 2024 Aug 1:jrheum.2023-1137. doi: 10.3899/jrheum.2023-1137.
    PubMed     Abstract available
    
    
    
69. GARG S, Plantinga LC
    A Bitter Pill to Swallow: The Challenge of Medication Nonadherence in Systemic Lupus Erythematosus.
    J Rheumatol. 2024 Aug 1:jrheum.2024-0654. doi: 10.3899/jrheum.2024-0654.
    PubMed     Abstract available
    
    
    July 2024
70. BOWDISH DME, Chandran V, Hitchon CA, Kaplan GG, et al
    When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study.
    J Rheumatol. 2024;51:721-727.
    PubMed     Abstract available
    
    
    
71. BAGGETT KH, Brandon TG, Xiao R, Weiss PF, et al
    Association of Infant Breastfeeding and Juvenile Spondyloarthritis: A Case-Control Study.
    J Rheumatol. 2024;51:708-714.
    PubMed     Abstract available
    
    
    
72. TANI C, Cardelli C, Zen M, Moroni L, et al
    Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study.
    J Rheumatol. 2024 Jul 1:jrheum.2024-0053. doi: 10.3899/jrheum.2024-0053.
    PubMed     Abstract available
    
    
    
73. TELES MS, Brundage J, Chiang TP, Alejo JL, et al
    Prevalence and Risk Factors of Post-Acute Sequela of COVID-19 in Adults with Systemic Autoimmune Rheumatic Diseases.
    J Rheumatol. 2024 Jul 1:jrheum.2023-1212. doi: 10.3899/jrheum.2023-1212.
    PubMed     Abstract available
    
    
    June 2024
74. UGARTE-GIL MF, Alarcon GS
    Low Disease Activity Early in the Course of Systemic Lupus Erythematosus.
    J Rheumatol. 2024 Jun 15:jrheum.2024-0502. doi: 10.3899/jrheum.2024-0502.
    PubMed     Abstract available
    
    
    
75. DHITAL R, Baer RJ, Bandoli G, Chambers C, et al
    Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals With Autoimmune and Rheumatic Diseases.
    J Rheumatol. 2024 Jun 15:jrheum.2024-0306. doi: 10.3899/jrheum.2024-0306.
    PubMed     Abstract available
    
    
    
76. KOBAYASHI H, Yoshida Y, Kida T, Yajima N, et al
    Seasonal Effects on Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Multicenter Cohort Study in Japan (J-CANVAS).
    J Rheumatol. 2024;51:646-648.
    PubMed    
    
    
    
77. KWOK TSH, Zhou AL, Nguyen EL, Kwan A, et al
    Preliminary Development of a Novel Tool to Document Vessel Wall Involvement in Patients With Large-Vessel Vasculitis.
    J Rheumatol. 2024;51:637-639.
    PubMed    
    
    
    
78. MISZTAL MC, Gold N, Cao J, Diaz T, et al
    Genetics of Neonatal Lupus Erythematosus Risk and Specific Manifestations.
    J Rheumatol. 2024 Jun 1:jrheum.2023-1036. doi: 10.3899/jrheum.2023-1036.
    PubMed     Abstract available
    
    
    
79. SUN K, Molokwu NJ, Hanlen-Rosado E, Corneli AL, et al
    Implementation of a clinician-led medication adherence intervention among patients with systemic lupus erythematosus.
    J Rheumatol. 2024 Jun 1:jrheum.2024-0071. doi: 10.3899/jrheum.2024-0071.
    PubMed     Abstract available
    
    
    May 2024
80. KANIECKI T, Moyers B, Lubinus M, Hu YP, et al
    Patient Perspectives of the Manifestations and Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis: An Observational Survey.
    J Rheumatol. 2024 May 15:jrheum.2024-0108. doi: 10.3899/jrheum.2024-0108.
    PubMed     Abstract available
    
    
    
81. AKPOIGBE O, Anim-Koranteng C, Tasmin R, Sammut A, et al
    A Rare Case of Anti-Mi-2 Antibody-Positive Dermatomyositis Associated With Gastrointestinal Stromal Tumor.
    J Rheumatol. 2024 May 15:jrheum.2024-0114. doi: 10.3899/jrheum.2024-0114.
    PubMed     Abstract available
    
    
    
82. AVASARALA J, Das S, Keshavamurthy S
    Point-of-Care Ultrasound With Artificial Intelligence-Driven Diagnostics in Giant Cell Arteritis: Blindness Prevention on a Global Scale.
    J Rheumatol. 2024 May 15:jrheum.2024-0217. doi: 10.3899/jrheum.2024-0217.
    PubMed     Abstract available
    
    
    
83. BRIDGES JM, Li J, Mannion ML, Clowse MEB, et al
    Contraception Care Patterns for Adult Females With Juvenile Idiopathic Arthritis on Teratogens in the Rheumatology Informatics System for Effectiveness (RISE) Registry.
    J Rheumatol. 2024;51:542-545.
    PubMed    
    
    
    April 2024
84. SEMALULU T, Berard R, Beattie K, Basodan D, et al
    Clinical Characteristics of Adolescents With Juvenile Idiopathic Arthritis Transitioning to Adult Rheumatology Care in Canada: Results From the CAPRI Registry.
    J Rheumatol. 2024;51:403-407.
    PubMed     Abstract available
    
    
    
85. OWN M, Bloostein A, Spiera R, Berman JR, et al
    Systemic Sclerosis in Individuals With Exposure to World Trade Center Ground Zero Rescue and Recovery Efforts: A Case Series.
    J Rheumatol. 2024;51:390-395.
    PubMed     Abstract available
    
    
    
86. CONTRERAS MARTIN GN
    Lupus Nephritis Treatment Strategies.
    J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172.
    PubMed     Abstract available
    
    
    
87. JUNEK M, Barra L, Kopp A, Felfeli T, et al
    Phase Specific Health Care Costs Associated with Giant Cell Arteritis in Ontario, Canada.
    J Rheumatol. 2024 Apr 1:jrheum.2023-1245. doi: 10.3899/jrheum.2023-1245.
    PubMed     Abstract available
    
    
    
88. ROBERTS JE, Faino A, Bryan MA, Cogen JD, et al
    Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus.
    J Rheumatol. 2024 Apr 1:jrheum.2023-1219. doi: 10.3899/jrheum.2023-1219.
    PubMed     Abstract available
    
    
    March 2024
89. YAMAMOTO H, Taniguchi Y
    Cranial Giant Cell Arteritis and Subdural Hematoma.
    J Rheumatol. 2024 Mar 15:jrheum.2024-0008. doi: 10.3899/jrheum.2024-0008.
    PubMed     Abstract available
    
    
    
90. YENNEMADI AS, Jordan N, Diong S, Keane J, et al
    The Link Between Dysregulated Immunometabolism and Vascular Damage: Implications for the Development of Atherosclerosis in Systemic Lupus Erythematosus and Other Rheumatic Diseases.
    J Rheumatol. 2024;51:234-241.
    PubMed     Abstract available
    
    
    
91. FALASINNU T, Nguyen T, Jiang TE, Tamang S, et al
    The Problem of Pain in Rheumatology: Variations in Case Definitions Derived From Chronic Pain Phenotyping Algorithms Using Electronic Health Records.
    J Rheumatol. 2024;51:297-304.
    PubMed     Abstract available
    
    
    
92. YASUDA N, Yamane T
    Leg Gangrene in Granulomatosis With Polyangiitis.
    J Rheumatol. 2024;51:316-317.
    PubMed    
    
    
    
93. PATEL NJ, Wang X, Lin M, Kowalski EN, et al
    Factors Associated with an Electronic Health Record-Based Definition of Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Disease.
    J Rheumatol. 2024 Mar 1:jrheum.2023-1092. doi: 10.3899/jrheum.2023-1092.
    PubMed     Abstract available
    
    
    
94. DAWOUD SA, Ahmad NU, Shriver EM, Chung SM, et al
    Orbital and Optic Nerve Sheath Involvement and Pupil-Involving Cranial Nerve 3 Palsy in Giant Cell Arteritis.
    J Rheumatol. 2024 Mar 1:jrheum.2023-1195. doi: 10.3899/jrheum.2023-1195.
    PubMed     Abstract available
    
    
    
95. MORAND EF, Jones SA
    Flare in Systemic Lupus Erythematosus: Lost in Translation?
    J Rheumatol. 2024 Mar 1:jrheum.2024-0122. doi: 10.3899/jrheum.2024-0122.
    PubMed     Abstract available
    
    
    February 2024
96. TAKEUCHI T, Wakasugi N, Hashida T, Uno S, et al
    Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10-year analysis of the real-world TRUST study.
    J Rheumatol. 2024 Feb 15:jrheum.2023-0210. doi: 10.3899/jrheum.2023-0210.
    PubMed     Abstract available
    
    
    
97. WALSH M, Strouse J, Bettendorf B
    Paget Disease as a Rare Mimicker of Giant Cell Arteritis.
    J Rheumatol. 2024 Feb 15:jrheum.2023-1160. doi: 10.3899/jrheum.2023-1160.
    PubMed     Abstract available
    
    
    
98. SAGY I, Schwarzfuchs O, Zeller L, Ling E, et al
    Short- and Long-Term Mortality of Hospitalized Patients with Autoimmune Rheumatic Diseases and Serious Infections: A National Cohort Study.
    J Rheumatol. 2024 Feb 1:jrheum.2023-1063. doi: 10.3899/jrheum.2023-1063.
    PubMed     Abstract available
    
    
    
99. ALPERS CE
    Antiphospholipid Antibodies (aPL) and Thrombotic Microangiopathy for the Diagnosis of aPL Nephropathy: You Can't Have One Without the Other.
    J Rheumatol. 2024;51:109-111.
    PubMed    
    
    
    
100. PEDERSEN MJ, Host C, Hansen SN, Deleuran BW, et al
     Psychiatric Morbidity Is Common Among Children With Juvenile Idiopathic Arthritis: A National Matched Cohort Study.
     J Rheumatol. 2024;51:181-188.
     PubMed     Abstract available
     
     
     December 2023
101. ROGERS JL, Clowse MEB, McKenna K, Starling S, et al
     Patient and physician perspectives of systemic lupus erythematosus flare: A qualitative study.
     J Rheumatol. 2023 Dec 15:jrheum.2023-0721. doi: 10.3899/jrheum.2023-0721.
     PubMed     Abstract available
     
     
     
102. SKYDEL JJ, Ramachandran R, Suttiratana S, Ross JS, et al
     Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies.
     J Rheumatol. 2023 Dec 15:jrheum.2023-0920. doi: 10.3899/jrheum.2023-0920.
     PubMed     Abstract available
     
     
     November 2023
103. TOUMA Z, Parodis I, Strand V
     More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus.
     J Rheumatol. 2023 Nov 15:jrheum.2023-0947. doi: 10.3899/jrheum.2023-0947.
     PubMed     Abstract available
     
     
     
104. RUBENSTEIN E, Maldini C, Vaglio A, Bello F, et al
     Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis.
     J Rheumatol. 2023;50:1446-1453.
     PubMed     Abstract available
     
     
     
105. ROZENBLYUM EV, Chan MO, Gakhal NK
     Chew on This: The Afterbite of Temporomandibular Joint Involvement in Adults With Juvenile Idiopathic Arthritis.
     J Rheumatol. 2023;50:1364-1366.
     PubMed    
     
     
     
106. RUPERTO N, Lovell DJ, Berman A, Anton J, et al
     Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.
     J Rheumatol. 2023;50:1471-1480.
     PubMed     Abstract available
     
     
     
107. DE SONNAVILLE WFC, Speksnijder CM, Zuithoff NPA, Heijstek MW, et al
     Clinically Established Temporomandibular Involvement in Adults With Juvenile Idiopathic Arthritis.
     J Rheumatol. 2023;50:1462-1470.
     PubMed     Abstract available
     
     
     
108. OGURO N, Yajima N, Ishikawa Y, Sakurai N, et al
     Impact of Attending Rheumatologist's Big Five Personality Traits on Systemic Lupus Erythematosus Patients' Trust: The TRUMP2-SLE Project.
     J Rheumatol. 2023 Nov 1:jrheum.2023-0603. doi: 10.3899/jrheum.2023-0603.
     PubMed     Abstract available
     
     
     October 2023
109. SUN YS, Huang DF, Chen WS, Liao HT, et al
     Risk factor and incidence of serious infections in systemic lupus erythematosus patients undergoing rituximab therapy.
     J Rheumatol. 2023 Oct 15:jrheum.2023-0623. doi: 10.3899/jrheum.2023-0623.
     PubMed     Abstract available
     
     
     
110. PARREAU S, Dumonteil S, Gondran G, Bezanahary H, et al
     Frequency and Significance of Hepatic Involvement in New-Onset Giant Cell Arteritis: A Study of 514 Patients.
     J Rheumatol. 2023 Oct 15:jrheum.2023-0358. doi: 10.3899/jrheum.2023-0358.
     PubMed     Abstract available
     
     
     
111. KAWANO Y, Wang X, Patel NJ, Qian G, et al
     Breakthrough COVID-19 after tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases.
     J Rheumatol. 2023 Oct 15:jrheum.2023-0742. doi: 10.3899/jrheum.2023-0742.
     PubMed     Abstract available
     
     
     
112. NIETO-GONZALEZ JC, Garulo DC, Boteanu A, Trives-Folguera L, et al
     What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?
     J Rheumatol. 2023;50:1326-1332.
     PubMed     Abstract available
     
     
     
113. AGUIRRE A, DeQuattro K, Shiboski S, Katz P, et al
     Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus.
     J Rheumatol. 2023;50:1302-1309.
     PubMed     Abstract available
     
     
     
114. LIU S, Han L, Li M, Tian X, et al
     Sex Differences in Clinical Manifestations of Hospitalized Patients With Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Cohort Study.
     J Rheumatol. 2023;50:1318-1325.
     PubMed     Abstract available
     
     
     
115. QUINTANA R, Ramirez-Flores MF, Fuentes-Silva Y, Pelaez-Ballestas I, et al
     Diagnostic Delay in Autoimmune Rheumatic Diseases: A Global Health Problem.
     J Rheumatol. 2023 Oct 1:jrheum.2023-0847. doi: 10.3899/jrheum.2023-0847.
     PubMed     Abstract available
     
     
     September 2023
116. PESKIN M, Mostowy M, Velez J, Perron M, et al
     Clinical improvement in early onset interstitial lung disease using rituximab in children with anti-MDA5 positive juvenile dermatomyositis.
     J Rheumatol. 2023 Sep 15:jrheum.2023-0544. doi: 10.3899/jrheum.2023-0544.
     PubMed     Abstract available
     
     
     
117. SASAI T, Nakashima R, Tsuji H, Nakajima T, et al
     Long term prognosis of anti-melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease.
     J Rheumatol. 2023 Sep 15:jrheum.2023-0371. doi: 10.3899/jrheum.2023-0371.
     PubMed     Abstract available
     
     
     
118. YOSHIDA Y, Nakamoto N, Oka N, Kidoguchi G, et al
     Seasonal Influence on Development of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Conducted at Multiple Institutions in Japan (J-CANVAS).
     J Rheumatol. 2023;50:1152-1158.
     PubMed     Abstract available
     
     
     
119. WEISS PF, Brandon TG, Lambert RG, Biko DM, et al
     Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs in Juvenile Spondyloarthritis.
     J Rheumatol. 2023;50:1173-1177.
     PubMed     Abstract available
     
     
     
120. MOISEEV S, Bulanov N, Crnogorac M, Direskeneli H, et al
     Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multinational Retrospective Study.
     J Rheumatol. 2023;50:1145-1151.
     PubMed     Abstract available
     
     
     
121. FERUCCI ED
     Improving Outcomes in Systemic Lupus Erythematosus: The Importance of Access to Medications.
     J Rheumatol. 2023 Sep 1:jrheum.2023-0772. doi: 10.3899/jrheum.2023-0772.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.